Company: DHR
Filing Date: 2025-10-21
Form Type: 10-Q
Source: 0000313616-25-000182
Chunk: 117

Company: DANAHER CORP /DE/
Filing Date: 2025-10-21
Form: 10-Q
Item: Item 8
Chunk 117
---
 dilutive effect in 2025 of acquired businesses and the impact of a product line disposition which did not qualify as discontinued operations - 20 basis points

Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were favorably impacted by:

•First nine months of 2024 acquisition-related fair value adjustment to inventory - 15 basis points

•Higher 2025 core sales and the impact of product mix, net of the impact of changes in leverage from the Company’s operations and administrative cost structure and the impact of currency exchange rates - 5 basis points

Business Segments

Sales by business segment for each of the periods indicated were as follows ($ in millions):

 Three-Month Period EndedNine-Month Period Ended September 26, 2025September 27, 2024September 26, 2025September 27, 2024Biotechnology$1,798 $1,653 $5,260 $4,890 Life Sciences1,792 1,782 5,249 5,297 Diagnostics2,463 2,363 7,221 7,150 Total$6,053 $5,798 $17,730 $17,337 

For information regarding the Company’s sales by geographical region, refer to Note 4 to the accompanying Consolidated Condensed Financial Statements.

30

BIOTECHNOLOGY

The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines.  The Company’s solutions support a broad range of biotherapeutics including monoclonal antibodies, recombinant proteins, replacement therapies such as insulin and vaccines, as well as novel cell, gene, mRNA and other nucleic acid therapies.

Biotechnology Selected Financial Data 

 Three-Month Period EndedNine-Month Period Ended($ in millions)September 26, 2025September 27, 2024September 26, 2025September 27, 2024Sales$1,798 $1,653 $5,260 $4,890 Operating profit352 390 1,324 1,177 Depreciation38 36 110 113 Amortization of intangible assets231 218 672 650 Operating profit as a % of sales19.6